Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBM2001
- Development stage
- Unknown
- Lead developer
- Harbour BioMed
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
HBM2001 is a bispecific antibody developed by Harbour BioMed (HBMK) that simultaneously targets tumor necrosis factor-like ligand 1A (TL1A) and the p19 subunit of interleukin-23 (IL-23p19). This therapeutic candidate is designed for the treatment of inflammatory bowel disease (IBD), aiming to provide enhanced anti-inflammatory and anti-fibrotic effects by blocking two distinct but synergistic pathways involved in gut pathology. TL1A signaling is associated with mucosal inflammation and tissue remodeling, while IL-23 is a master regulator of the Th17-mediated immune response. By dual-targeting these pathways, HBM2001 is intended to offer superior efficacy compared to monotherapies. The drug is currently in Phase 1 clinical development.
- Other names
- HBM2001-HBMK-TL1A-IL23p19-bispecific antibody-Inflammatory Bowel Disease (IBD)TL1A x IL-23p19 bispecific antibodyTL-1A x IL-23p19 bispecific antibodyTL 1A x IL-23p19 bispecific antibody
02
Targets
TL1A (TNF-like cytokine 1A)IL23A (Interleukin-23 p19 Subunit)
Beyond the preview
Go deeper on HBM2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBM2001.